Nephro-Protective Effect of Kangqianling Decoction on Chronic Renal Failure Rats by Jia, Wei & NC DOCKS at The University of North Carolina at Greensboro
Nephro-Protective Effect of Kangqianling Decoction on Chronic Renal Failure Rats 
 
By: Liqun He, Peicheng Shen, Qiang Fu, Jun Li, Mo Dan, Xiaoyan Wang, and Wei Jia 
 
He, L., Shen, P., Fu, Q., Li, J., Dan, M., Wang, X., & Jia, W. (2009). Nephro-protective effect of 
Kangqianling decociton on chronic renal failure rats. Journal of Ethnopharmacology, 
122, 367-373. 
 
 
***Note: This version of the document is not the copy of record. Made available courtesy of 
Elsevier. Link to Full Text: 
http://www.sciencedirect.com/science/article/pii/S0378874108006946 
 
 
 
Abstract: 
Ethnopharmacological relevance: Kangqianling decoction (KQL), the modified formulation of a 
classical Chinese prescription named Taohongsiwu decoction, was clinically employed to treat 
renal fibrosis in chronic renal failure. 
Aim of the study: The present study was designed to examine whether KQL has a protective 
effect on renal function in association with transforming growth factor-β (TGF-β), angiotensin II 
(Ang II), tumor necrosis factor-α (TNF-α), nuclear factor-κB (NF-κB) in rats with 5/6 renal 
ablation (Nx)-induced chronic renal failure. 
Results: In renal function deterioration progression, the high expression of serum creatinine 
(Scr), 24-h urine protein and systolic blood pressure were markedly (P < 0.05 or P < 0.01) 
restored by KQL, respectively, at 4 and 8 weeks. The increasing expressions of renal Ang II 
(P < 0.05), angiotensin II1-receptor (AT1R) (P < 0.05), TNF-α (P < 0.05), NF-κB (P < 0.001) 
and urine TGF-β1 (P < 0.05) were reduced by the treatment of KQL. Immunohistochemical 
study further confirmed the nephro-protective activity of KQL as compared to the control and 
Sham group. 
Conclusions: The results indicate that KQL is able to protect renal function via ameliorating 
experimental rat renal failure as found in these renal functional parameters. 
 
Article: 
INTRODUCTION 
Some traditional Chinese herbal formulations documented in the ancient Chinese pharmacopoeia 
or monographs have been employed for chronic renal failure, especially at early and middle 
stage (He et al., 2003, Li et al., 2003, He and Cai, 2005a and He et al., 2005b). Kangqianling 
decoction (KQL), composed of radix salvia miltiorrhizae (Dansen), fructus jujubae (Dahuang), 
badix achyranthis bidentatae (Niuxi), and semen perwicae (Taoren), radix angelicae sinensis 
(danggui), was originated from one of the most famous Chinese prescription, Taohongsiwu 
decoction (compared with KQL, plus Paeonia, szechwan lovage rhizome flos carthami, and 
without fructus jujubae, badix achyranthis bidentatae), which has been widely used to treat 
hematomas (Jin et al., 2006), nephrotic syndrome (Guo, 2006) and chronic glomerulonephritis 
(Xia et al., 2007), etc. In clinical practice, KQL could significantly decrease serum creatinine 
(Scr) and blood urea nitrogen (BUN) as well as delayed progression of chronic renal failure. 
KQL could significantly lower creatinine and urea nitrogen of early metaphase chronic renal 
failure (CKD2-3) patients, and were widely used in the treatment of early metaphase chronic 
renal failure (Chen and He, 2006). 
 
Almost all progressive chronic renal failure is the consequence of destructive fibrosis, 
glomeruloscerosis and extracellular matrix hyperplasia. The fibrogenic signaling phase is 
characterized by the release of soluble factors that have fibrosis-promoting effects. Several 
growth factors and cytokines have been implicated with primary roles suggested for transforming 
growth factor-β (TGF-β), angiotensin II (Ang II) and endothelin-1. Additional factors may 
participate including platelet-derived growth factor, basic fibroblast growth factor, tumor 
necrosis factor-α (TNF-α) and interleukin-1 (IL-1) (Allison, 2000). Hypertension is usually 
associated with the development of vascular and renal fibrosis, which is characterized by 
structural changes in vasculature caused by increased synthesis and rearrangement of 
extracellular matrix proteins (Weistuch and Dworkin, 1992). Nuclear factor-κB (NF-κB), a 
family of dimeric transcription factors that regulate the expression of numerous genes involved 
in inflammation and cell proliferation, has been found to be activated in experimental renal 
disease. Importantly, NF-κB activation can be modulated by pharmacological maneuvers both in 
vivo and in vitro. Indeed, it is now widely acknowledged that the anti-inflammatory action of 
steroids is basically obtained through the inhibition of the transactivation of NF-κB-dependent 
genes. Additionally, some of the beneficial effects of angiotensin-converting enzyme inhibitors 
and statins may, at least in part, be mediated by an inhibition of NF-κB activation (Guijarro and 
Egido, 2001). 
 
There is little experimental data regarding probable molecular mechanisms of nephro-protective 
action of KQL on chronic renal failure although being used clinically for decades. Therefore, in 
the present investigation, we examined the effects of KQL against 5/6 renal ablation (Nx)-
induced chronic renal failure. At the same time, we investigate the influence of renal mass 
reduction (RMR) caused by Nx on gene expression of Ang II, AT1R, NF-κB, TNF-α and TGF-
β1 and evaluate the correlation between expression of these genes and activity of the intrarenal 
rennin–angiotensin systems. 
 
MATERIALS AND METHODS 
Animals 
Munich–Wistar rats (200 ± 20 g) (BiKai, Shanghai, China) were used for the study. All the rats 
were individually housed in stainless steel wire-mesh cages, and fed ad libitum with standard 
solid chow (BiKai Animal Lab. Company, Shanghai, China) containing 24.5% protein. Room 
temperature and humidity were regulated at 24 ± 1 °C and 45 ± 15%, respectively. All the 
procedures were in strict accordance with the PR China legislation on the use and care of 
laboratory animals and with the guidelines established by the Institute for Experimental Animals 
of Shanghai Jiao Tong University and were approved by the University Committee for animal 
experiments. 
 
Preparation of Kangqianling decoction 
KQL is composed of radix salvia miltiorrhizae (from province of Sichuan) 30 g, fructus jujubae 
(from province of Gansu) 9 g, badix achyranthis bidentatae (from province of Henan) 15 g, and 
semen perwicae (from province of Hebei) 12 g, radix angelicae sinensis (from province of 
Gansu) 15 g. All the herbal drugs were purchased from Shanghai Huayu Pharmaceutical Co., and 
identified by authority. The air-dried herbs were powdered and subjected to hot water extraction 
for 3 h. The extract was concentrated, precipitated with 4 times alcohol, free of the solvent and 
then finally dispersed and dissolved in hot water and then cooled for rat administration. Final 
yield of prepared decoction was above 35%. 
 
Experimental procedure 
Animals were divided into three groups: Sham Group (normal Sham-control), Control Group 
(empty vehicle-treated control), Treatment Group (received KQL), each group containing 12 
animals. According to literatures with little modification (Ng et al., 1998 and Goncalves et al., 
2004), at first, the left kidneys of 24 Munich–Wistar rats were 2/3 renal ablated. After 1 week, 
the right kidneys were ablated. These procedures were performed under anaesthesia with sodium 
pentobarbital (Shanghai Pharmaceutical Factory, Shanghai, China). Two weeks after Nx, the 24 
rats were divided into 12 pairs, where two rats in each pair exhibited almost the same levels of 
Scr, BUN (Table 1). Then one rat of each pair were collected to be Treatment Group received 
KQL (n = 12), at a daily dose of 0.75 g (crude herbal drugs)/100 g (body weight), converted 
according to clinical human dosage, orally for 8 weeks. The others were allocated to be Control 
Group (vehicle control, n = 12) received empty vehicle parallel. For Sham Group, rats underwent 
a Sham operation consisting of laparotomy and manipulation of the renal pedicles but without 
damage to the kidney (n = 12). 
 
Table 1: Effect of KQL on serum creatinine (Scr), blood urea nitrogen (BUN) and 24-h urinary protein excretion. 
Group N BUN (mmol/L)  Scr (μmol/L) 24 h urine protein (mg) 
  Before treatment Fourth week Eighth week  Before treatment Fourth week Eighth week Eighth week 
Sham 12 7.51 ± 0.75 6.79 ± 0.70 9.31 ± 1.05  19.00 ± 4.00 26.25 ± 1.04 18.88 ± 1.55 22.34 ± 4.4 
Control 12 16.17 ± 0.99* 12.09 ± 3.37 14.85 ± 2.83  49.50 ± 6.53* 50.56 ± 15.83 53.38 ± 12.05 41.47 ± 8.07 
Treatment 12 16.18 ± 2.42* 9.81 ± 2.93 13.62 ± 2.81  49.23 ± 9.36* 38.83 ± 12.00# 41.00 ± 10.51## 29.14 ± 5.68## 
Values are means ± S.E.M. 
*P < 0.05, compared with Sham Group. 
#P < 0.05, compared with Control Group. 
##P < 0.01, compared with Control Group. 
 
Blood pressure was measured before treatment and every 2 weeks after the surgery. The levels of 
Scr, BUN, 24 h urine protein excretion and urine TGF-β were determined at 4 or 8 weeks after 
starting the administration of KQL, respectively. On the eighth week, the animals were sacrificed 
and the remnant kidneys were collected for histopathological and gene expression studies. 
 
Assessment of renal function and blood pressure. Scr and BUN was measured using a 
Beckman Cx4 analyser (Fullerton, CA, USA), respectively. 24 h urinary protein concentrations 
were determined by the Bradford method, adapted to a microtiter plate assay. Coomassie reagent 
(USB, Cleveland, OH) was added to the diluted urine samples. After 10 min, the absorbance at 
595-nm wavelength was read on ELX800 microplate reader (Bio-Tek Instruments, VT). The 
protein concentrations were calculated by reference to bovine serum albumin (Sigma) standards. 
Systolic blood pressure was recorded by tail plethysmography using the BP2000 blood pressure 
analysis system (Visitech Systems, Inc., Apex, NC) in conscious rats at baseline and every 2 
weeks throughout the experimental time course. 
 
Assessment of immunohistochemistry. Immunostaining of NF-κB in renal tissue sections was 
performed using the streptavidin–biotinylated peroxidase complex (SABC) method (Muller et 
al., 2000). The immunostaining of NF-κB was quantified using an image analyser IMS (FUDAN 
University of Medical Science Portrait Examination Center, Shanghai, China) by evaluating the 
positively stained area of the sections under the same light intensity for microscopy. 
 
Real-time quantitative polymerase chain reaction (PCR) for TNF-α, Ang II and AT1R. To 
investigate the mRNA expression of TNF-α, Ang II and angiotensin II1-receptor (AT1R), real-
time PCR (BC Living Creature Technique Co., Shanghai, China) was performed on the Opticon 
machine (FX Scientific Research Inc., Shanghai, China) ( [Karkar et al., 1992], [Ruiz-Ortega and 
Egido, 1997], [Wolf et al., 1999] and [Goncalves et al., 2004]). Briefly, total RNA was extracted 
from renal tissues and cultured cells by homogenization in TRIzol (Trizol box, from GIBCO 
BRC Inc., Shanghai, China). All of the RNA samples were treated with the RNase-free DNase I 
(GIBCO BRC Inc., Shanghai, China) before the RT-PCR. Real-time quantitative one-step RT-
PCR assay was performed to quantify mRNA using real-time PCR machine (FX Scientific 
Research Inc., Shanghai, China). The primers used for real-time RT-PCR were as follows: 
 
TNF-α: forward 5′-CTCATTCCCGCTCGTGG-3′; reverse 3′-
CGTTTGGTGGTTCGTCTCC-5′; 
 
AT1R: forward 5′-CTTGTTCCCTTTCCTTATC-3′; reverse 3′-ACTCCACCTCAC 
TGTCCA-5′; 
 
Ang II: forward 5′-ACCTG CATGA GTGTT GATAGG-3′; reverse 3′-ACTTCA 
ATATC GTCAGTAACTGGAC-5′. 
 
Quantitative analyses of TNF-α, Ang II and AT1R expressions were performed using a 
quantitative image analysis system FR-2000 (FR Science and Technology Inc., Shanghai, 
China). 
 
Characterization of monoclonal anti-TGF-β antibody. The reactivity of the produced 
monoclonal antibodies with urine TGF-β was screened by enzyme-linked immunosorbent assay 
(ELISA) using kit produced by Section Living Creature Technique Limited Company of 
Hangzhou, China (NO. 13409007) (Houlihan et al., 2002). 
 
Statistical analysis 
Results were expressed as the means ± S.E.M. Statistical analyses were performed using 
GraphPad Prism 3.0 (GraphPad Software, Inc., San Diego, CA). Differences in blood pressure, 
Scr, BUN, 24 h urine protein and Urine TGF-β at different time points (weeks 0–8) among the 
groups, and differences of Ang II and AT1R activation, TNF-α expression and NF-κb 
accumulation in Sham Group, Control Group, Treatment Group were assessed by one-way 
analysis of variance (AOWAV) and t-test to judge whether the results were statistically 
significant. The critical p-value of both tests was set to 0.05 in this study. 
 
 
 
RESULT 
Effects of KQL on physiological biochemical parameters of Nx rats 
Renal and systemic parameters were obtained at 0, 4 and 8 weeks after Nx given (Table 1) (Fig. 
1, Fig. 2, Fig. 3, Fig. 4 and Fig. 5). In Control Group, body weights were statistically different 
from those observed before treatment. Average food intake was similar among groups. There 
was significant change in body weight between the control Nx rats and treated Nx rats, although 
they were pair-fed. The body weights of KQL treated rats were significantly higher than empty 
vehicle treated ones. Even 4 weeks after Nx, the levels of Scr and BUN of Nx rats were 
markedly increased as compared with Sham rats. In renal function deterioration progression, the 
high expression of Scr and BUN were observed in the end of experimental research, while Scr 
was markedly restored by KQL, respectively, at both 4 and 8 weeks. Urinary protein excretion 
was also suppressed obviously at eighth week as compared with Nx rats in Control Group. 
 
 
Figure 1: Effect of KQL on inhibiting renal NF-κB accumulation within the kidney in immunohistochemistry 
results. The accumulation of NF-κB in the glomerular and tubulointerstitium is demonstrated from Sham rats (A and 
B), Control rats (C and D), and Treatment rats (E and F) (original magnifications 100×). 
 
Figure 2: Semiquantitative analysis of the therapeutic effect of KQL on NF-κB localization in the glomerulus and 
tubulointerstitium using the Quantitative Image System. Percentage of glomerular and tubulointerstitial NF-κB 
deposition in Sham Group (A), Control Group (B) and Treatment Group (C). Each value represents 
mean ± S.E.M. #P < 0.05, ##P < 0.001 compared with Control Group; *P < 0.05, **P < 0.01, compared with Sham 
Group. 
 
 
 
Figure 3: Real-time PCR of renal Ang II mRNA expression of representative rats in each group and 
semiquantitative analysis of the therapeutic effect of KQL on Ang II mRNA localization in the glomerulus and 
tubulointerstitium. Degree of glomerular and tubulointerstitial Ang II mRNA expression in Sham Group (A), 
Control Group (B) and Treatment Group (C). Each value represents mean ± S.E.M. #P < 0.05, ##P < 0.001 compared 
with Control Group; *P < 0.05, **P < 0.01, compared with Sham Group. 
 
Figure 4: Real-time PCR of renal AT1R mRNA expression of representative rats in each group and 
semiquantitative analysis of the therapeutic effect of KQL on AT1RmRNA localization in the glomerulus and 
tubulointerstitium. Degree of glomerular and tubulointerstitial AT1RmRNA expression in Sham Group (A), Control 
Group (B) and Treatment Group (C). Each value represents mean ± S.E.M. #P < 0.05, ##P < 0.001 compared with 
Control Group; *P < 0.05, **P < 0.01, compared with Sham Group. 
 
 
 
Figure 5: Real-time PCR of renal TNF-α mRNA expression of representative rats in each group and 
semiquantitative analysis of the therapeutic effect of KQL on TNF-α mRNA within the glomerulus and 
tubulointerstitium. Degree of glomerular and tubulointerstitial TNF-α mRNA expression in Sham Group (A), 
Control Group (B) and Treatment Group (C). Each value represents mean ± S.E.M. #P < 0.05, ##P < 0.001 compared 
with Control Group; *P < 0.05, **P < 0.01, compared with Control Group. 
 
Effects of KQL on mean arterial blood pressure of uraemic rats 
After subtotal nephrectomy, hypertension developed in both Control Group and Treatment 
Group. Compared with Sham Group, blood pressure was significantly elevated from 2 to 8 
weeks after nephrectomy (P < 0.05 or 0.01), and the rise in blood pressure was equivalent 
(systolic blood pressure 180–200 mmHg) in Control Group. After using KQL, hypertension was 
obviously suppressed in Treatment Group, showing average systolic blood pressure from 140 to 
160 mmHg (Table 2). 
 
Table 2: Effect of KQL on systolic blood pressure (mmHg). 
Group N Before treatment After treatment 
   Second week Fourth week Sixth week Eighth week 
Sham 12 137.31 ± 14.72 139.13 ± 14.06 125.50 ± 7.15 150.56 ± 13.97 129.63 ± 29.16 
Control 12 140.50 ± 23.55* 212.46 ± 43.26 199.92 ± 23.55 156.33 ± 20.72 202.44 ± 15.09 
Treatment 12 141.77 ± 26.45* 148.50 ± 38.82## 152.46 ± 29.54## 141.00 ± 14.73# 176.00 ± 30.70# 
Values are means ± S.E.M. 
*P < 0.05, compared with Sham Group. 
#P < 0.05, compared with Control Group. 
##P < 0.01, compared with Control Group. 
 
Effects of KQL on urine TGF-β1 of uraemic rats 
High urine excretion of TGF-β1 was expressed in both glomerular and tubulointerstitial injuries. 
To further demonstrate the anti-inflammatory effect of the extract on rat chronic renal failure, the 
TGF-β1 level was determined in the urine by ELISA. The results showed that compared with 
vehicle, KQL significantly reduced urinary TGF-β1 levels, corrected by decrease level of Scr, 
throughout the entire disease course (P < 0.05), indicating that the treatment may primarily 
suppress the local immune and inflammatory response within the diseased kidney. In contrast, 
over expression of urine TGF-β1 was found in control uraemic rats as compared with normal rats 
in Sham Group (Table 3). The experimental result showed the KQL administration significantly 
inversed high expression of urine TGF-β in Nx rats, manifesting which attenuated the 
development of glomerular sclerosis. 
 
Table 3: Effect of KQL on urine TGF-β excretion. 
Group N Urine TGF-β (μg/L) 
Sham 12 1.83 ± 0.64 
Control 12 1.90 ± 0.56* 
Treatment 12 1.77 ± 0.43# 
Values are means ± S.E.M. 
*P < 0.05, compared with Sham Group. 
#P < 0.05, compared with Control Group. 
 
Effects of KQL on localization of NF-κB in renal tissue 
Immunohistochemical analysis was performed to determine the localization of NF-κB in the 
renal cortex (Fig. 1 and Fig. 2). NF-κB, a critical transcriptional factor controlling inflammatory 
response, played a central role in inflammatory diseases, including kidney diseases (Muller et al., 
2000). In normal rats, only tubular epithelial cells were weakly stained by the monoclonal anti-
NF-κB antibody, while glomeruli were hardly stained. In control Nx rats, however, proximal 
tubular epithelial cells, especially dilated tubules, were intensively stained by the anti-NF-κB 
antibody. In contrast, activation of the NF-κB in tubular epithelial cells was not prominent in the 
KQL treated rats. The staining of NF-κB as shown in the control Nx rats increased NF-κB-
positive (intensively stained) area in the renal cortex, whereas the treated rats indicated markedly 
decreased NF-κB-positive area. These data demonstrated that KQL markedly reduced the 
overload of NF-κB on the remnant tubular cells. 
 
Effects of KQL on mRNA levels of TNF-α, Ang II and AT1R in renal tissue 
The effects of KQL on the gene expression of Ang II (Fig. 3), AT1R (Fig. 4) and TNF-α (Fig. 5) 
in the renal cortex were examined. We investigated the potential mechanisms whereby KQL 
suppressed rat tubular interstitial fibrosis and glomerular cirrhosis. In control Nx rats, there was a 
substantial increase in renal mRNA expression of TNF-α, TNF-α inflammatory genes were 
significantly up-regulated by the treatment with KQL (P < 0.05). Furthermore, the mRNAs of 
Ang II and AT1R in renal cortex were attenuated by KQL compared with the control uraemic 
rats when they were administered after the establishment of nephrectomized. However, the renal 
mRNA levels of Ang II and AT1R were markedly increased in control Nx rats as compared with 
normal rats. The variation in the mRNA levels of TNF-α, Ang II and AT1R in both treated and 
control uraemic rats are related to variation in the extent of CRF. 
 
DISCUSSION AND CONCLUSION 
The present study showed a protective action of KQL treatment in the chronic renal failure rats 
induced by Nx, which promoted growth retardation, systemic arterial hypertension, impaired 
renal function, and severe albuminuria (Goncalves et al., 2004). These functional changes were 
accompanied by severe glomerulosclerosis, as well as expansion and intense macrophage 
infiltration of the interstitial area. Previous study indicated that these renal structural 
abnormalities, characteristics of the Nx and other models of progressive nephropathies, are a 
consequence of the concerted action of mechanical stress, caused by glomerular hypertension 
and hypertrophy, and inflammatory phenomena, comprising cell infiltration and/or proliferation 
and extracellular matrix accumulation (Fujihara et al., 2003). Moreover, a causal relationship 
appears to exist between these phenomena, because the distension of the glomerular walls due to 
intracapillary hypertension may trigger the local release of cytokines, growth factors, and, 
particularly, Ang II and AT1R (Lee et al., 1995). 
 
We examined the renal function of rats including Scr, BUN and 24 h urine protein. Scr 
demonstrate the ability of kidney to remove creatinine from the blood and concentrate it in the 
urine. Renal dysfunction diminishes the ability to filter creatinine and so the Scr rises. Diseased 
or damaged kidneys cause an elevated BUN because the kidneys are less able to clear urea from 
the bloodstream. 24 h urine protein also reflected the function of kidney. Nx rats showed 
significant raise of Scr, BUN and 24 h urine protein, however, the apparently restored levels in 
Treatment Group indicating that KQL significant improve the kidney function of the Nx rat. 
 
Hypertension is an important result in chronic renal disease and is associated with a more rapid 
rate of progression (Hannedouche et al., 1993). Therapeutic measures aiming to lower high blood 
pressure in progressive renal diseases have been widely used. Administration of KQL 
contributed a great beneficial effect against hypertension caused by the chronic renal failure. 
 
The production of extracellular matrix proteins in the interstitium is regulated and induced by 
growth factors derived from macrophages and tubular cells. In this process, one of the most 
relevant mediators is the TGF-β. KQL treatment group prevented the up-regulation of TGF-β to 
the level of Sham control group, indicating that KQL showed protection against fibrogenic 
process. 
 
Intrarenal Ang II distribution was profoundly changed after renal mass reduction (Noronha et al., 
2002). In the process of renal disease progression another local mediator, Ang II, deserves 
consideration. Besides its hemodynamic effects, Ang II exerts actions on cells that contribute to 
inflammation and tissue fibrosis which favor the pathogenesis of renal disease. A preliminary 
report has suggested that, in the Nx model, Ang II is expressed in renal interstitial cells, 
paralleling the severity of renal injury (Noronha et al., 2002). In the present study, an increase in 
Ang II level was observed in control Nx rats, and was decreased in Treatment Group, indicating 
KQL may prevent the chronic renal failure by regulating local mediator, Ang II. 
 
Renal expression of AT1R in rats appeared mostly in tubular cells, and to a lesser extent, at the 
interstitial area, whereas low expression was seen in vessels and glomeruli. This pattern was 
completely disrupted after Nx, when dense AT1R expression could be demonstrated in 
interstitial cells, far exceeding in intensity the expression of AT1R in tubules. The exact meaning 
of this finding and the cell types involved are uncertain. The simultaneous presence at the 
interstitial area of large amounts of Ang II and AT1R may accelerate the progression of the 
nephropathy by a positive-feedback mechanism. Consistent with this view is the aggravation of 
the renal structural injury of Nx, which was paralleled by the intensity of the inflammatory 
infiltration and of the interstitial expression of Ang II. 
 
It has been thought that Ang II induces vascular fibrosis by stimulating TGF-β. Accordingly, 
TGF-β induction is the initial step in promoting fibrosis during vascular remodeling in response 
to Ang II. Ang II and TGF-β are critical mediators of renal fibrosis (Gaedeke et al., 2001). Ang II 
may mediate renal scarring through TGF-β stimulation (Rumble et al., 1998 and Houlihan et al., 
2002). In our study, the urinary TGF-β excretion was in good accordance with the level of Ang 
II. At the same time, the increased TGF-β level had been restored to the Sham group level in the 
KQL treatment group. 
 
NF-κB, a well accepted key transcriptional factor to regulate a variety of inflammatory responses 
(Barnes and Karin, 1997), is composed of p50 and p65 subunits, among which p65 is a potent 
transcriptional activator, strongly promoting inflammatory reaction in kidney diseases (Guijarro 
and Egido, 2001). In our study, using liquid extract isolated from clinical effective Chinese 
prescription, over expression activation of NF-κB was substantially suppressed. The result 
explained one of the mechanisms of KQL to improve renal function and correct high blood 
pressure. 
 
Tumor necrosis factor-α is a potent pro-inflammatory cytokine which is produced by many cell 
types including monocytes/macrophages, and renal mesangial and epithelial cells. TNF-α may 
contribute to renal damage by inciting an inflammatory response within the kidney via induction 
of a variety of chemokines and adhesion molecules (Tipping et al., 1999). The TNF-α 
expressions within the glomerulus and tubulointerstitium were significantly different in the KQL 
treatment group compared with the control group, which may due to the anti-inflammatory 
function of KQL through preventing the expression of TNF-α. 
 
On the basis of the present study, the efficacy of KQL was likely due to the simultaneous 
blockade of the hemodynamic and pro-inflammatory actions of Ang II, AT1R and its derivatives 
as TNF-α, NF-κB, TGF-β and by abrogation of the complex interplay between hypertension and 
inflammation. It is noteworthy that KQL afforded partial regression of the chronic renal failure 
induced by Nx model. This observation suggests that continued stimulation of Ang II, AT1 
receptors and production of inflammatory factors played an important pathogenic role even 
during the late phases of the process, KQL was a vigorous and persistent treatment to prevent 
further renal deterioration. 
 
In conclusion, KQL administration ameliorates renal dysfunction, renal fibrosis and down-
regulate many critical anti-inflammatory factors in rats with Nx-induced chronic renal failure. 
Taken together with our previous works (He et al., 2003 and He and Cai, 2005a) and the present 
results, it is likely that KQL-induced reduction of renal rennin–angiotensin system is mediated, 
at least partly, by reducing the overload of inflammatory factors activity on remnant kidney unit. 
In summary, KQL partially reversed the nephropathy and renal inflammation associated with the 
Nx model. Clinical mechanism studies are further needed to establish how this scheme may 
eventually become a new weapon in the limited arsenal available to attenuate or prevent human 
progressive chronic renal failure. 
 
ABBREVIATIONS 
KQL   Kangqianling decoction  
Scr   serum creatinine 
BUN   blood urea nitrogen 
Nx   5/6 renal ablation  
TGF-β1  transforming growth factor-β1  
Ang II   angiotensin II  
TNF-α   tumor necrosis factor-α  
NF-Κb   nuclear factor-κB 
AT1R   angiotensinII1-receptor 
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